» Articles » PMID: 10371349

Molecular Mediators of Tumor Angiogenesis: Enhanced Expression and Activation of Vascular Endothelial Growth Factor Receptor KDR in Primary Breast Cancer

Overview
Journal Int J Cancer
Specialty Oncology
Date 1999 Jun 17
PMID 10371349
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The progression of breast cancer growth and its ability to metastasize are associated with the process of angiogenesis. In this study, we examined the protein expression of vascular endothelial growth factor (VEGF) and its specific and functional receptor KDR in human breast tissue. We investigated a total of 13 mammary carcinomas, 3 fibroadenomas, 5 specimens with fibrocystic breast disease as well as normal (adjacent to malignant) breast tissue using immunohistochemistry and Western blot analysis. In all carcinomas examined, functional KDR protein was present independent of tumor type, tumor stage and histological grade as demonstrated by tyrosine phosphorylation analysis of KDR. When malignant tissues were compared with their neighboring non-neoplastic regions, activated KDR was found to be expressed to a much higher extent within the malignant tissue samples. In fibroadenomas, KDR was barely detectable, whereas in fibrocystic breast disease KDR expression was variable. Immunostaining of KDR was localized to endothelium and epithelium of mammary ducts in malignant and benign breast tissue, while VEGF immunoreactivity was primarily found in the endothelium and also in tumor cells and macrophages. Our data demonstrate that KDR activation is enhanced in breast cancer in vivo and emphasize the functional role of VEGF and KDR in the development of malignant breast disease.

Citing Articles

The impact of intraoperative radiotherapy on breast cancer: focus on the levels of angiogenic factors.

Nafissi N, Mohammadlou M, Akbari M, Mahdavi S, Sheikh M, Borji M World J Surg Oncol. 2022; 20(1):191.

PMID: 35681234 PMC: 9178821. DOI: 10.1186/s12957-022-02653-8.


Oxidative stress and angiogenesis in primary hyperparathyroidism.

Deska M, Romuk E, Segiet O, Bula G, Truchanowski W, Stolecka D Eur Surg. 2017; 49(3):118-126.

PMID: 28596785 PMC: 5438426. DOI: 10.1007/s10353-016-0457-6.


Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies.

Nasir A, Holzer T, Chen M, Man M, Schade A Cancer Cell Int. 2017; 17:56.

PMID: 28533703 PMC: 5438568. DOI: 10.1186/s12935-017-0427-5.


In situ validation of VEGFR-2 and α v ß 3 integrin as targets for breast lesion characterization.

Ehling J, Misiewicz M, von Stillfried S, Mockel D, Bzyl J, Pochon S Angiogenesis. 2016; 19(2):245-254.

PMID: 26902100 PMC: 5432025. DOI: 10.1007/s10456-016-9499-4.


Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts.

Imoukhuede P, Popel A Cancer Med. 2014; 3(2):225-44.

PMID: 24449499 PMC: 3987073. DOI: 10.1002/cam4.188.